Burzynski Research Institute Inc BZYR:OTCPK

*Data is delayed | Exchange | USD
Last | 04/23/24 EDT
0.0418UNCH (UNCH)
52 week range
0.01 - 0.09
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0418
  • 52 Week High0.09
  • 52 Week High Date05/24/23
  • 52 Week Low0.01
  • 52 Week Low Date02/02/24

Key Stats

  • Market Cap5.492M
  • Shares Out131.45M
  • 10 Day Average Volume3,446.67
  • Dividend-
  • Dividend Yield-
  • Beta1.44
  • YTD % Change-5.05

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0418
  • 52 Week High0.09
  • 52 Week High Date05/24/23
  • 52 Week Low0.01
  • 52 Week Low Date02/02/24
  • Market Cap5.492M
  • Shares Out131.45M
  • 10 Day Average Volume3,446.67
  • Dividend-
  • Dividend Yield-
  • Beta1.44
  • YTD % Change-5.05

RATIOS/PROFITABILITY

  • EPS (TTM)-0.01
  • P/E (TTM)-4.62
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-1.189M
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Burzynski Research Institute Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Burzynski Research Institute, Inc. is engaged in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids, which are known under the trade name Antineoplastons. Antineoplastons are useful in the treatment of human cancer and is reviewing data from its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons are...
Stanislaw Burzynski M.D., Ph.D.
Chairman of the Board, President
Tomasz Janicki M.D.
Vice President - Clinical Trials
Address
12000 Richmond Ave
Houston, TX
77082
United States